JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

Revvity Inc

Closed

SectorHealthcare

91.71 -1.25

Overview

Share price change

24h

Current

Min

91.6

Max

94.18

Key metrics

By Trading Economics

Income

-8.6M

47M

Sales

-21M

699M

P/E

Sector Avg

47.923

77.256

EPS

1.18

Dividend yield

0.3

Profit margin

6.675

Employees

11,000

EBITDA

-14M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.5% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.30%

2.33%

Next Dividend date

7 lis 2025

Next Ex Dividend date

16 sty 2026

Market Stats

By TradingEconomics

Market Cap

-486M

11B

Previous open

92.96

Previous close

91.71

News Sentiment

By Acuity

27%

73%

27 / 373 Ranking in Healthcare

Revvity Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 lis 2025, 23:57 UTC

Earnings

Naver's Third-Quarter Earnings Rose on AI Push

4 lis 2025, 23:10 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4 lis 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 lis 2025, 23:48 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4 lis 2025, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4 lis 2025, 23:30 UTC

Earnings

Itau Unibanco 3Q Net BRL33.7B >ITUB

4 lis 2025, 23:25 UTC

Earnings

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4 lis 2025, 23:25 UTC

Earnings

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4 lis 2025, 23:24 UTC

Earnings

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4 lis 2025, 23:23 UTC

Earnings

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4 lis 2025, 23:06 UTC

Earnings

Review & Preview: Tech Check -- Barrons.com

4 lis 2025, 22:52 UTC

Earnings

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4 lis 2025, 22:33 UTC

Earnings

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4 lis 2025, 22:29 UTC

Earnings

Ashland 4Q Adj EPS $1.08 >ASH

4 lis 2025, 22:29 UTC

Earnings

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4 lis 2025, 22:28 UTC

Earnings

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q Cont Ops EPS 73c >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q EPS 71c >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q Sales $478M >ASH

4 lis 2025, 22:23 UTC

Earnings

Ovintiv 3Q EPS 57c >OVV

4 lis 2025, 22:19 UTC

Market Talk

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4 lis 2025, 22:16 UTC

Earnings

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4 lis 2025, 22:14 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4 lis 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4 lis 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Consortium: Able to Finance a Deal With Available Liquidity

4 lis 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4 lis 2025, 22:11 UTC

Earnings

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4 lis 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4 lis 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 lis 2025, 22:07 UTC

Earnings

Kinross Gold Raises Dividend to $0.035 >K.T

Peer Comparison

Price change

Revvity Inc Forecast

Price Target

By TipRanks

19.5% upside

12 Months Forecast

Average 111.1 USD  19.5%

High 125 USD

Low 100 USD

Based on 11 Wall Street analysts offering 12 month price targets forRevvity Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

27 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat